Biotechnology Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 – Entera Bio (NASDAQ:ENTX) Read more
Biotechnology Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024 Read more
Biotechnology Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome – Entera Bio (NASDAQ:ENTX) Read more
Biotechnology Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU Read more
